TMED11 Conference
Shaping Future Healthcare with Clinical Research and Personalised Prescribing
Join us at the historic Guildhall, Derry-Londonderry for the 11th TMED Conference – a leading international event in translational medicine bringing together clinical researchers, academics, industry partners and healthcare innovators from across the UK and Europe.
Poster 17- Could ABO blood group and PIV serve as prognostic markers to support personalised treatment in advanced NSCLC? A 5-year-real world study from Northern Ireland
Authors: Hebaallah Elsandoby1, Ryan Hacket 2, Claire O’Neil 2, Sara Hassan Shams Eldin1, Mariam A.Saleh1, Praveen Baskar1, Ruba Hamed2, Raafat A. Malek1
Affiliations: 1 North West Cancer Centre, Derry/Londonderry, Northern Ireland. 2 Northern Ireland Cancer Centre, Belfast.
Background/ Introduction: First-line pembrolizumab, as monotherapy (PD-L1 ≥50%) or combined with chemotherapy regardless of PD-L1, is standard in advanced NSCLC without actionable mutations. Despite improved survival, robust, accessible prognostic biomarkers for checkpoint inhibitor therapy remain limited. ABO blood group and systemic inflammation markers, including the pan-immune-inflammation value (PIV) derived from routine blood counts, have emerged as potential prognostic factors.
Material & Methods: We retrospectively analysed 333 patients with locally advanced/metastatic NSCLC treated with first-line pembrolizumab ± chemotherapy in Northern Ireland (2019–2024). Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan–Meier methods. Associations with clinicopathological variables (PD-L1, histology, haemoglobin, toxicity, ABO blood group, PIV) were assessed. Baseline PIV was calculated prior to cycle 1 and categorised using a predefined cut-off. ABO data were available in 129 patients.
Results: At a median follow up period of 20 months, the median PFS and OS were 8.1 and 21.2 months, respectively. ABO blood group significantly influenced outcomes; group O showed improved PFS and OS compared with other blood groups. On multivariate analysis, blood group O was independently associated with superior PFS (p=0.005) and OS (p=0.018); while PIV <1000 independently predicted improved OS (p=0.006) but not PFS (p=0.051). Treatment-related toxicity was associated with improved PFS on univariate but not on multivariate analysis. PD-L1 expression and histology were not independently predictive of outcomes.
Conclusion: ABO blood group and PIV are independent prognostic biomarkers in advanced NSCLC treated with pembrolizumab. ABO blood group is a novel, easily accessible biomarker associated with immunotherapy outcomes and warrants prospective validation. Systemic inflammation, as reflected by PIV, independently predicts overall survival and may support risk stratification and personalised treatment approaches.
